Back to results
US 11,396,647 B2Granted
Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
AssigneeBoard of Regents, The University of Texas System
InventorEverett Stone
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions related to conjugated polypeptides with MTA/ADO-degrading enzyme activity. The conjugated polypeptides are engineered to allow for maximal conjugation while maintaining catalytic activities. Also disclosed are nucleic acids, expression vectors, and host cells related to the conjugated polypeptides. Further disclosed are methods of using the pharmaceutical formulations comprising above to treat cancer.
Claims19
A composition comprising a polypeptide having methylthioadenosine phosphorylase activity,
- wherein said polypeptide comprises an amino acid sequence with at least 95% sequence identity to at least 100 consecutive amino acids of SEQ ID NO:
- 1 and comprises amino acids corresponding to Threonine 18, Threonine 197, Serine 178, Valine 233 and Methionine 196 of SEQ ID NO:
- 1, and
- wherein an amino acid corresponding to Lysine 225 or Lysine 238 of SEQ ID NO:
- 1 is (i) deleted or (ii) substituted with Alanine, Arginine, Asparagine, Aspartic Acid, Cysteine, Glutamine, Glutamic Acid, Glycine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, or Valine.
2 more elements
Dependencies are inferred from the claim text.